Research Paper Volume 15, Issue 13 pp 6400—6428
Exploring Cancer Dependency Map genes and immune subtypes in colon cancer, in which TIGD1 contributes to colon cancer progression
Figure 6. Drug IC50 analysis in CDM risk signature (blue represents low CDM risk group, red represents high group). (A) AMG.706 (p=0.025); (B) AP.24534 (p=0.0014); (C) Axitinib (p=6.9e^-6); (D) AZD.0530 (p=0.012); (E) AZD7762 (p=0.0032); (F) Epothilone (p=0.04); (G) Etoposide (p=0.033); (H) Imatinib (p=0.02); (I) IPA.3 (p=0.0026); (J) Lenalidomide (p=0.00067); (K) Nilotinib (p=0.0051); (L) PD.173074 (p=0.0027); (M) Shikonin (p=0.0016); (N) Vinblastine (p=0.0085); (O) Vinorelbine (p=0.028).